TL;DR: ParcelBio is a Y Combinator Winter 2024 startup Elevated mRNA for transformative medicines., currently active with a team of 6.
Elevated mRNA for transformative medicines.
Last verified:
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
Built by LemStudio
Yes. ParcelBio was funded by Y Combinator in the Winter 2024 batch. Elevated mRNA for transformative medicines.
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clin…
ParcelBio was part of Y Combinator's Winter 2024 batch.
ParcelBio has a team of 6 people according to Y Combinator's directory.
ParcelBio is currently listed as Active with a team of 6 in Y Combinator's directory.
Loading interactive view…